Human immunodeficiency virus type 1 (HIV-1) strains dually resistant to zidovudine and lamivudine (3TC) may arise during zidovudine-3TC combination therapy. The objective of this crosssectional study (n Å 43 patients) was to test the association between therapy response (clinical and immunologic) to zidovudine-3TC and the level of phenotypic zidovudine resistance and zidovudine resistance -associated genotype of 3TC-resistant isolates. Other variables included were baseline CD4 / cell count, baseline Centers for Disease Control and Prevention (CDC) classification, virus load, and time receiving zidovudine. Phenotypic resistance was assessed using a recombinant virus assay. Genotypic analysis was based on population sequencing of plasma HIV-1. In a univariate analysis using a logistic regression model, it was found that therapy response was significantly associated with phenotypic and genotypic zidovudine resistance, baseline CD4
The effectiveness of zidovudine-lamivudine (zidovudineof reverse transcriptase (M184V) is selected [9 -11] and has been detected 4 -12 weeks after initiation of 3TC monotherapy 3TC) combination therapy was first demonstrated in four independent surrogate marker trials in antiretroviral-untreated [1, or zidovudine-3TC combination treatment in virtually all HIV-1 -infected patients tested [12, 13] . M184V is accompanied by 2] and in zidovudine-pretreated patients [3, 4] . A significant clinical benefit in favor of 3TC-containing treatment arms was increases of 100-to 500-fold in the IC 50 of 3TC for patientderived HIV-1 isolates or recombinant viruses [13, 14] . shown by a metaanalysis of these four trials [5] , and more recently, in a clinical end-point trial comparing zidovudineResistance to zidovudine, on the other hand, develops gradually by the stepwise accrual of mutations, including substitucontaining standard-of-care nucleoside analogue treatment combinations plus or minus 3TC in a patient population with tions at positions 41, 67, 70, 210, 215, and 219 [15 -20] . The quantity and the pattern of mutations influence the level of more advanced disease [6] . A benefit for 3TC has also been demonstrated in triple combinations with human immunodefiphenotypic resistance [18 -21] .
The mechanisms proposed to explain the observed continued ciency virus type 1 (HIV-1) protease inhibitors [7] or nonnucleoside reverse transcriptase inhibitors [8] .
benefit of zidovudine-3TC combination therapy in spite of the high level of 3TC resistance include: a mutational interaction Under conditions of continuing viral replication, a highly 3TC-resistant virus population containing a methionine-to-vabetween M184V and zidovudine resistance-associated mutations, which results in a reversal of zidovudine resistance in virus strains line substitution at amino acid residue 184 in the catalytic site carrying zidovudine resistance-associated mutations [11, 14] ; delay of zidovudine resistance development in the presence of 3TC (and M184V) [14] ; reduction of HIV-1 reverse transcriptase activ-JID 1998;177 (June) combination therapy in previously naive patients) and continuing assays [34, 37, 39] or by the detection of specific mutations to 4 weeks after the sample date for resistance analysis. [36, 38, 39] .
Resistance analysis on consecutive samples was done for 12
The association of zidovudine resistance development assopatients. Only the first sample from each patient was included in ciated with zidovudine-3TC treatment with clinical progression the analyses.
has not been examined to date. In zidovudine-3TC -treated
Preparation of recombinant HIV-1 from patient plasma. Re- patients, a dissociation between the prognostic value for thercombinant HIV-1 for the HeLa CD4 / plaque-reduction assay were apy failure of the presence of zidovudine resistance -associated constructed as previously described [14, 19, 41] . The primers used mutations versus phenotypic resistance may be expected due were: OUT3 (5-CATTGCTCTCCAATTACTGTGATATTTCTto the M184V resensitization effect. We therefore sought to CATG-3) for reverse transcription, OUT5 analyze the genotypic and phenotypic patterns of resistance to and OUT3 for the first-round polymerase chain reaction (PCR), and IN5 (5-AATzidovudine in a cross-sectional study of patients treated long-TTTCCCATTAGTCCTATTGAAACTGTACCAG-3) and IN3
term with zidovudine-3TC who appeared to be having therapy failure on the basis of declining CD4 cell counts. for the first-round reaction. All reactions were carried out in a Biometra Uno Thermocycler (Biometra, Göttingen, Germany). Reter of the Frankfurt University Hospital (Frankfurt, Germany) during 1993-1996 as participants in controlled trials [2, 3] or as part action conditions for both PCR rounds were as follows: 95ЊC for 3 min followed by 30 cycles of 90ЊC for 1 min, 55ЊC for 30 s, of the 3TC compassionate use program. We included all participants of the NUCB3001 and 3002 trials for whom plasma samples and 72ЊC for 2 min. PCR products were purified (QIAquick PCR Purification Kit; Qiagen) and analyzed by 1% agarose gel electrowere available at the time that resistance testing became available. Thus, we had 16 patients from the NUCB3002 trial (for zidovudphoresis. The amplification product (5 mg) and linearized reverse transcriptase-deleted proviral clone pHIV᭝RT (10 mg) were ine-pretreated patients) and 3 patients from the NUCB3001 trial (for therapy-inexperienced patients). At the time of sampling, the transfected into MT4 cells using the Gene Pulser (Bio-Rad, Hercules, CA) in 0.4-cm electrode cuvettes at 250 mF and 300 V. randomized and open-label follow-up trial periods were finished, and these patients were being treated with zidovudine-3TC within After a 30-min incubation at room temperature, 10 mL of fresh culture medium was added, and the cells were incubated at 37ЊC the compassionate use program as part of an ongoing therapy regimen. In addition, we included all patients who had begun 3TC in a humidified atmosphere. Stocks of chimeric viruses were harvested from the culture supernatant. treatment through the NUCB3004 protocol (compassionate use), for whom resistance testing had been performed as part of therapy Drug susceptibility assays. Phenotypic susceptibilities to zidovudine and 3TC were assessed using the HeLa plaque-reduction monitoring because therapy changes were being considered (24 patients). Patients were seen every 4-8 weeks. Plasma samples plasma-derived recombinant virus assay (RVA) and the MTT-MT4 assay (Antivirogram) as previously described [41] [42] [43] . Rewere obtained and stored at 070ЊC for plasma HIV-1 RNA measurements and resistance analysis. Information regarding immunosults are expressed as the fold-resistance (fold-increase in IC 50 relative to wild-type) or the log 10 of the fold-resistance value logic status and clinical progression was collected retrospectively from the case report forms and/or patients' medical files. For the (log 10 -R). Resistance analyses were carried out in a blinded fashion with respect to therapy response. purposes of this analysis, the follow-up period was defined as starting at baseline (the date 3TC therapy was started (either added Sequence analysis. The sequences of the reverse transcriptase-coding regions from recombinant viruses were deterto a preexisting zidovudine therapy or as part of zidovudine-3TC JID 1998;177 (June)
Resistance to AZT-3TC and Therapy Failure mined by population sequencing as previously described [44] . In and 233 cells/mm 3 for patients with sensitive or low-resistance isolates. The patients with high-resistance isolates were also more advanced in terms of clinical status (CDC classification). The total time receiving zidovudine did not correlate with the level Results of phenotypic resistance. In 12 patients, 2 consecutive samples were tested, with a Patient population characteristics. An analysis of phenotypic resistance to nucleoside analogue reverse transcriptase time interval of 1 -8 months. The second sample showed either an increased level or level of zidovudine resistance similar to inhibitors was performed on plasma samples from 43 zidovudine-3TC -treated patients. The patient characteristics are sumthe first (data not shown). Under zidovudine monotherapy, the level of zidovudine remarized in table 1. Thirty-two patients had been treated with zidovudine and 3TC only; 11 patients had also received other sistance has been reported to vary according to the number and pattern of zidovudine-associated mutations [15, 16, 18, 19, 21] . nucleoside analogues at some point in their treatment histories. All except 1 were zidovudine-experienced at the time of initiaWe therefore examined the relation between the total number of zidovudine resistance -associated mutations (at positions 41, tion of zidovudine-3TC treatment. The time of zidovudine pretreatment ranged from 0 to 66 months (median, 18); the time 67, 70, 210, 215, and 219) and phenotypic zidovudine resistance in this zidovudine-3TC -treated population. Genotypic of zidovudine-3TC treatment ranged from 6 to 30 months (median, 17). The patient population as a whole had relatively data were available for 40 of the 43 patients. Figure 1A shows that there was no significant correlation beadvanced disease, with a median baseline CD4 cell count of 124 cells/mm (P Å .69). All samples with no or 1 mutation were phenotypically count was not available). Sixteen patients had therapy failure on the basis of both criteria. sensitive or hypersensitive to zidovudine. Phenotypic resistance in samples with two zidovudine resistance-associated mutations
We first examined the relationship between zidovudine phenotypic resistance and clinical progression (occurrence of ranged between õ10-fold and ú100-fold. Figure 1B shows the level of phenotypic resistance in relation to the mutational pattern.
new class B or C events or progression from class A to B and from class B to C), as shown in figure 2. Resistance to Most isolates contained both the M41L and T215Y/F mutations; therefore, it was not possible to analyze the relationship between zidovudine in patients who were in category A at baseline (start of 3TC therapy) and remained in this category until the presence of one or both of these mutations and phenotypic resistance. The level of zidovudine resistance in HIV-1 recombithe end of the follow-up period ranged from 00.4 to 0.95 log 10 -R, with a median log 10 -R value of 0 (or 1-fold). Connants carrying both the 41 and 215 mutations ranged from 6-fold to 1062-fold. However, of 32 samples containing M41L / versely, progression from CDC category A to B was associated with a median log 10 -R of 1.89 (P Å .08). Similarly, T215Y/F, 19 also carried the L210W mutation. The median level of zidovudine resistance was higher in the samples carrying all 3 resistance in patients who started in category B and remained there without experiencing new class B events was lower mutations (median log 10 -R Å 2.16) compared with samples with mutations at position 41 and 215 but wild-type at position 210 than in patients who progressed from category B to category C (medians, 1.15 and 2.08, respectively, P Å .007). A differ-(median log 10 -R Å 1.23). This difference was statistically significant (P õ .001).
ence was also seen in the median resistance in patients who were class B at baseline and who remained there but had No nonnucleoside reverse transcriptase inhibitor resistanceassociated mutations known to influence phenotypic zidovunew class B events compared with those without new class B events (median log 10 -R 2.2 vs. 1.15, P Å .02) and in padine resistance [45, 46] were detected.
Zidovudine resistance and response to zidovudine-3TC thertients who were class C at baseline who had new class C events compared with those without new class C events, apy. Of the 43 patients, 21 had clinical progression while receiving zidovudine-3TC, and 29 had therapy failure on the although the latter difference was not statistically significant (median log 10 -R 2.24 vs. 2.09, P Å .30). basis of CD4 cell count (for 2 patients, the baseline CD4 cell Table 2 . Baseline characteristics of HIV-1 -infected patients divided into 3 groups on the basis of the level of HIV-1 resistance to zidovudine. We next analyzed the number of clinical events during folintermediate-level zidovudine resistance, and 13 had samples with high-level zidovudine resistance. In contrast, samples from low-up as a function of zidovudine resistance ( figure 3 ). The analysis shows that no events occurred in patients with a zidopatients in the RR group did not yield any recombinant viruses with high-level zidovudine resistance. In this group, the majority vudine resistance value õ10-fold. In contrast, a total of 66 events per 21 patients (39 CDC class B and 27 CDC class C (6/9) had samples with sensitive or low-level zidovudine resistance samples. The association of phenotypic resistance with events) had occurred in the 21 patients with high-level zidovudine resistance. The intermediate-level group (13 patients) had therapy response was highly statistically significant (P õ .001, Kruskal-Wallis nonparametric analysis). a total of 10 clinical events (5 CDC class B and 5 CDC class C). The difference in the number of clinical events was statistically Baseline plasma virus load data were not available for this patient population. However, we were able to determine the significant (P õ .001, Kruskal-Wallis test).
The actual levels of zidovudine resistance per sample and the virus load for the time point at which the sample for resistance testing was taken for 41 of the 43 patients. Figure 5 shows that patient's response to zidovudine-3TC treatment, defined as a composite measure of clinical and CD4 cell count responses, are a statistically significant correlation exists between virus load at time of sampling and zidovudine resistance (R Å .59, P õ illustrated in figure 4 . The median log 10 -R for patients experiencing clinical progression and a negative CD4 curve (therapy re-.001, Spearman's rank correlation coefficient). The association of resistance, baseline CD4 cell count, basesponse category FF) was 2.12 (range, 1.15-3.03), whereas the median log 10 -R for patients remaining clinically stable with a line CDC category, virus load, and total time receiving zidovudine treatment with therapy response (clinical plus CD4 cell CD4 cell count still above baseline (therapy response category RR) was 0 (range, 00.7 to 1.67). Patients who had one of the count) was analyzed statistically using a logistic regression model with a three-level response variable (based on response two failure-defining criteria showed a median resistance value of 2.34 (therapy response category FR) and 1.23 (therapy response categories FF, FR/RF, and RR, as defined for figure 4) . The results of a univariate analysis are listed in unadjusted). The level of phenotypic resistance and the extent ment remained statistically significant after adjusting for the extent of genotypic change and all other variables, with relative of genotypic changes associated with zidovudine resistance were both highly significantly associated with therapy response, odds of 4.67 (CI, 1.09 -19.9, P Å .04), whereas the number of genotypic changes was not associated with therapeutic rewith relative odds of a better response of 6.59 (confidence interval [CI], 2.63 -16.6, P ú .001) and 2.03 (CI, 1.37 -3.01, sponse. Finally, as shown in column 5, an analysis including only the two types of resistance measurements demonstrated P õ .001), respectively. Virus load at sample time and the CD4 cell count at the start of zidovudine-3TC combination that phenotypic zidovudine resistance retains a highly significant association with therapeutic response, with relative odds treatment were also statistically associated, with relative odds of 3.67 (CI, 1.65 -8.20, P Å .002) and 2.23 (CI, 1.24 -4.03, P of 5.84 (CI, 1.87 -18.1, P Å .003) after adjustment for the extent of genotypic resistance, whereas genotypic resistance Å .008), respectively. The association of baseline CDC classification with therapy response was not statistically significant was not associated with therapeutic response after adjustment for phenotype. Similar results were obtained when the geno-(relative odds of 2.17; CI, 0.92 -5.12, P Å .08).
A series of multivariate analyses was performed (table 3, typic pattern (mutations at position 41 / 215 vs. 41 / 210 / 215 vs. other combinations) was used instead of number of columns 2 -5). Columns 2 and 3 show that after adjusting for baseline CD4 cell count, baseline CDC category, virus load, mutations. The association of therapeutic response with phenotypic zidovudine resistance remained statistically significant and time receiving zidovudine, phenotypic resistance (column 2) and genotypic resistance (column 3) remained associated (relative odds, 4.93, P Å .003), whereas the association with genotypic resistance was not significant (data not shown). with therapy response at a statistically significant level, with relative odds of 6.00 (CI, 1.88 -19.0, P Å .002) and 2.02 (CI, 1.21 -3.35, P Å .006), respectively. In contrast, when adjusted Discussion for the other variables, baseline CD4 cell count and virus load were not associated with therapy response. Columns 4 and 5
In this cross-sectional analysis of phenotypic resistance to zidovudine and 3TC in plasma-derived recombinant HIV-1 show results of multivariate analyses, taking into consideration both types of resistance measurements. The association befrom zidovudine-3TC -treated patients, we have demonstrated that dual resistance to these drugs can develop in vivo in zidotween therapeutic response and phenotypic resistance measure-/ 9d46$$ju09 04-02-98 23:05:02 jinfal UC: J Infect vudine-3TC -treated patients with therapy failure. None of the virus load, and time receiving zidovudine therapy in this zidovudine-3TC -treated patient population. There was no correlapatients still responding to zidovudine-3TC therapy had highlevel zidovudine resistance; conversely, none of the patients tion between zidovudine resistance and the total time receiving zidovudine treatment. with both clinical and immunologic failure had zidovudinesensitive isolates, but rather, 76% had highly resistant isolates.
Although the zidovudine resistance -associated genotype (based on changes at positions 41, 67, 70, 210, 215, and 219) Phenotypic resistance to zidovudine was associated with the presence of zidovudine-specific mutations; however, the range was associated at a significant level with therapeutic response in univariate and multivariate analyses including the above variof phenotypic resistance was wide, and in samples with more than two zidovudine mutations, more mutations did not transables, detection of resistance at the genotypic level lost significance after adjusting for the level of phenotypic resistance. In late into a higher level of resistance.
Phenotypic resistance to zidovudine in 3TC-resistant isothis last analysis, phenotypic zidovudine resistance was the only significant factor associated with therapeutic response. lates was significantly associated with clinical progression, with the number of clinical events occurring during followThese results derive from analysis of a small, primarily zidovudine-pretreated patient population. As this was neither a lonup, and with virus load at the time of sampling. On the basis of a composite measure of therapy response involving HIVgitudinally followed nor a randomized patient population, no general conclusions as to the incidence of dual resistance during 1 -associated clinical events and immunologic response, both phenotypic and genotypic resistance to zidovudine were sigzidovudine-3TC therapy can be drawn. It will be of interest to examine the response to zidovudine-3TC -containing combinanificantly associated with therapy failure, along with virus load and baseline CD4 cell count. Multivariate analysis tion therapies in zidovudine-pretreated patients based on virus load and zidovudine resistance status at the start of 3TC thershowed that zidovudine resistance was the only significant factor associated with therapeutic response after adjustment apy. For our patient population, however, baseline samples were not available for virologic investigations. for baseline CD4 cell count, baseline CDC status, plasma / 9d46$$ju09 04-02-98 23:05:02 jinfal UC: J Infect In our study, an association of zidovudine resistance with the absence of baseline samples, we were not in a position to demonstrate M184V-mediated reversal of zidovudine resisimmediately preceding rather than subsequent therapeutic response was observed; therefore, the role of resistance in therapy tance in this patient population. However, zidovudine susceptibility was observed in patients with zidovudine resistancefailure cannot be defined. Nevertheless, we have shown that such an association is relevant for zidovudine-3TC therapy. Other associated genomic changes. Although the ddI resistance -associated genotypic change at position 74 (LeujVal) also has studies have demonstrated an association of zidovudine resistance with subsequent clinical progression in patients treated with zidobeen shown to reverse zidovudine resistance in vitro [53] , the incidence of this mutation under zidovudine-ddI therapy is not vudine monotherapy [34] [35] [36] [37] [38] [39] [40] . Although development of zidovudine resistance was correlated with baseline clinical status and as frequent as the M184V under 3TC [54] . Furthermore, the ability of 74V to reverse zidovudine resistance is only minimal CD4 cell count, the association of resistance and clinical development during zidovudine therapy was independent of these variwhen mutations at both positions 41 and 215 are present [55] .
Whether zidovudine resistance is associated with a poor ables [35, 37, 38] . Zidovudine resistance in our population of patients with 3TC-resistant viruses was also associated with a prognosis when patients are switched to other combination therapies, such as triple combinations including protease inhibilower clinical and immunologic status at baseline (in this case, start of 3TC therapy), while the response to therapy was associtors, remains to be determined. The ACTG 116B/117 trial demonstrated that high-level zidovudine resistance represented ated with resistance independently of these baseline variables. In addition, phenotypic resistance to zidovudine as well as therapy a relative risk of 1.74 (95% CI, 1.00 -3.03) for clinical progression independent of a therapy switch to ddI monotherapy; on response based on clinical and immunologic status were significantly associated with virus load at the end of the follow-up the other hand, a switch to ddI after a minimum of 16 weeks of zidovudine monotherapy was beneficial, independent of period, as would be expected [47] [48] [49] [50] .
On the basis of in vitro observations of mutational interacwhether the isolates were highly resistant to zidovudine or not [37] . In that study, it may not have been possible to detect a tions, virus isolates containing zidovudine resistance -associated mutations at the six positions examined in this study would relationship based on a more differentiated measurement of resistance. Similarly, in an accompanying mutational analysis be expected to remain susceptible. This would imply that additional mutations must contribute to the development of dual [38] , a significant association with clinical progression was found if the patients' isolates contained mutations at positions resistance to zidovudine and 3TC. Preliminary data from sequence analysis of the complete reverse transcriptase coding 41 and 215 but not if a mutation was present at position 215 only, independent of whether patients continued to receive ziregion indicate that changes in other positions do occur with a higher frequency in dually resistant samples, and some of dovudine monotherapy or were switched to ddI. Other studies have shown an association between the presthese have been shown to contribute to dual resistance by sitedirected mutagenesis [51] . The significance and contribution ence of the T215F/Y mutation in isolates from zidovudine monotherapy -treated patients and a subsequent poor response of these changes to dual resistance and therapeutic response to zidovudine-3TC therapy are currently being investigated. A to ddI [56] . An association between the level of phenotypic zidovudine resistance and cross-resistance to dideoxycytidine recent report, based on an analysis of 4 patients, found that a minimum of three zidovudine resistance -associated mutations (ddC) and ddI has been reported [57] . In a study of M184V-mediated cross-resistance to ddC and ddI in zidovudine-3TC -were required for zidovudine resistance to develop in HIV-1 from 3TC-pretreated patients [52] . Our data indicate that in treated patients, we have also observed an association of resistance to ddC and ddI with the level of phenotypic resistance some cases, two of the well-characterized zidovudine mutations may be sufficient for high-level zidovudine resistance and point to zidovudine [58] . These considerations may in part explain the ''zidovudine resistance -independent'' benefit of a switch to the role of background genotype in determining the level of zidovudine resistance.
to ddI in the ACTG 116B/117 trial as well as the treatment assignment -independent association of poor prognosis with Using plasma-derived viral material, the incidence of M184V in HIV from 3TC-treated patients was 98% in the zidovudine resistance. This would indicate that a certain level of zidovudine resistance would lead to poor therapeutic represent study (95% in a previous study [14] ). In only 1 of 54 samples from patients reportedly receiving 3TC therapy at the sponses when patients are switched to combinations in which nucleoside analogues are the major component. time of sampling did we detect 3TC susceptibility, albeit slightly decreased. Differences with other published incidences
The methods for phenotypic resistance detection used in this study are based on direct amplification of circulating HIV-(e.g., 70% after 12 weeks of therapy [29] ) may be due to methodologic differences and may reflect differences in kinet-1 reverse transcriptase. The RVA allows a determination of resistance compared with wild-type on an individual sample ics of detectable resistance in proviral versus plasma RNAderived material [13] .
level rather than population means or baseline samples. This methodology has several advantages over the classic peripheral Reversal of zidovudine resistance by M184V and delay or inhibition of zidovudine resistance development have been docblood mononuclear cell coculture-based assays: It measures the resistance associated with plasma-derived viral RNA rather umented in vitro and implicated in the 3TC-associated benefit of zidovudine-3TC combination therapy [14, 25, 26] tant and partially resistant isolates [54] . 
